{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:01:13Z","timestamp":1777662073059,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1996,5]]},"DOI":"10.1212\/wnl.46.5.1459","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:19:55Z","timestamp":1336915195000},"page":"1459-1459","update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":66,"title":["Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose"],"prefix":"10.1212","volume":"46","author":[{"given":"Ognen A.C.","family":"Petroff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin L.","family":"Behar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Mattson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmac 1989;27(Suppl 1):19S\u201322S.","DOI":"10.1111\/j.1365-2125.1989.tb03456.x"},{"key":"e_1_3_1_3_2","unstructured":"Jung MJ Palfreyman MG. Vigabatrin: mechanisms of action. In: Levy RH Mattson RH Meldrum BS eds. Antiepileptic drugs. 4th ed. New York: Raven Press 1995:903\u2013913."},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Bolton JB Rimmer E Williams J Richens A. The effect of vigabatrin on brain and platelet GABA-transaminase activities. Br J Clin Pharmac 1989;27(Suppl 1):35S\u2013425.","DOI":"10.1111\/j.1365-2125.1989.tb03459.x"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1994.62010001.x"},{"key":"e_1_3_1_6_2","first-page":"4","volume":"35","year":"1994","unstructured":"Preece NE, Jackson GD, Houseman JA, Duncan JS, Williams SR. Nuclear magnetic resonance detection of increased cortical GABA in vigabatrin-treated rats in vivo. Epilepsia 1994;35:431\u2013436.","journal-title":"Epilepsia"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00965160"},{"key":"e_1_3_1_8_2","first-page":"3","volume":"143","year":"1987","unstructured":"L\u00f6scher W, Frey HH. One to three day dose intervals during subchronic treatment of epileptic gerbils with gamma-vinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels. Eur J Pharmacol 1987;143:335\u2013342.","journal-title":"Eur J Pharmacol"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.1.1"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Mumford JP Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmac 1989;27(Suppl 1):101S\u2013107S.","DOI":"10.1111\/j.1365-2125.1989.tb03469.x"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.1.1"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Ben-Menachem E Persson LI Schechter PJ et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmac 1989;27(Suppl 1):79S\u2013855.","DOI":"10.1111\/j.1365-2125.1989.tb03466.x"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Reikkinen PJ Ylinen A Halonen T Sivenius J Pitk\u00e4nen A. Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Pharmac 1989;27(Suppl 1):87S\u201394S.","DOI":"10.1111\/j.1365-2125.1989.tb03467.x"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1993.tb05816.x"},{"key":"e_1_3_1_15_2","first-page":"2","volume":"16","year":"1993","unstructured":"Ben-Menachem E, Hamberger A, Mumford J. Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system-a case study. Epilepsy Res 1993;16:241\u2013243.","journal-title":"Epilepsy Res"},{"key":"e_1_3_1_16_2","first-page":"5","volume":"90","year":"1993","unstructured":"Rothman DL, Petroff OAC, Behar KL. Mattson RH. Localized 1H NMR measurements of GABA levels in human brain in vivo. Proc Natl Acad Sci USA 1993;90:5662\u20135666.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_1_17_2","first-page":"4","volume":"80","year":"1983","unstructured":"Behar KL, den Hollander JA, Stromski ME, et al. Highresolution 1H nuclear magnetic resonance study of cerebral hypoxia in vivo. Proc Natl Acad Sci USA 1983;80:4945\u20134948.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_1_18_2","first-page":"6","volume":"81","year":"1984","unstructured":"Rothman DL, Behar KL, Hetherington HP, Shulman RG. Homonuclear 1H-double resonance difference spectroscopy of the rat brain in vivo. Proc Natl Acad Sci USA 1984;81:6330\u20136334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.1.1"},{"key":"e_1_3_1_20_2","first-page":"6","volume":"31","year":"1994","unstructured":"Behar K, Boehm D. Measurement of GABA following GABA-transaminase inhibition by gabaculine: a 1H and 31P NMR spectroscopic study of rat brain in vivo. Magn Reson Med 1994;31:660\u2013667.","journal-title":"Magn Reson Med"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Mattson RH Petroff O Rothman D Behar K. Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. Epilepsia 1994;53(Suppl 5):S29\u2013S32.","DOI":"10.1111\/j.1528-1157.1994.tb05963.x"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01644.x"},{"key":"e_1_3_1_23_2","first-page":"2","volume":"32","year":"1994","unstructured":"Behar KL, Rothman DL, Spencer DD, Petroff OAC. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn Reson Med 1994;32:294\u2013302.","journal-title":"Magn Reson Med"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.1.1"},{"key":"e_1_3_1_25_2","unstructured":"Gardner MJ Altman DG. Statistics with confidence. London: British Medical Journal 1989."},{"key":"e_1_3_1_26_2","first-page":"2","volume":"2","year":"1988","unstructured":"Halonen T, Lehtinen M, Pitk\u00e4nen A, Ylinen A, Riekkinen PJ. Inhibitory and excitatory amino acids in CSF of patients suffering with complex partial seizures during chronic treatment with gamma-vinyl GABA (vigabatrin). Epilepsy Res 1988;2:246\u2013252.","journal-title":"Epilepsy Res"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Ben-Menachem E Persson LI Mumford JP Haegele KD Huebert N. The effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. J Child Neurol 1991;6(Suppl 2):2S11-2S16.","DOI":"10.1177\/0883073891006002041"},{"key":"e_1_3_1_28_2","first-page":"2","volume":"50","year":"1993","unstructured":"Pitk\u00e4nen A, Ylinen A, Matilainen R, et al. Long-term antiepileptic efficacy of vigabatrin in drug-refractory epilepsy in mentally retarded patients: a 5 year follow-up study. Arch Neurol 1993;50:24\u201329.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_29_2","unstructured":"Penry JK Wilder BJ Sachdeo RC et al. Multicenter dose-response study of vigabatrin in adults with focal (partial) epilepsy [abstract]. Epilepsia 1993;34(Suppl 6):67."},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"Mumford JP Cannon DJ. Vigabatrin. Epilepsia 1994;35 (Suppl 5):S25\u2013S28.","DOI":"10.1111\/j.1528-1157.1994.tb05962.x"},{"key":"e_1_3_1_31_2","first-page":"8","volume":"23","year":"1984","unstructured":"Bernasconi R, Bittiger H, Schmutz M, Martin P, Klein M. Is the estimation of the GABA turnover rate in vivo a tool to differentiate between various types of drugs interfering with the GABA\/benzodiazepine\/ionophore receptor complex? Neuropharmacology 1984;23:815\u2013816.","journal-title":"Is the estimation of the GABA turnover rate in vivo a tool to differentiate between various types of drugs interfering with the GABA\/benzodiazepine\/ionophore receptor complex? Neuropharmacology"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1979.tb11698.x"},{"key":"e_1_3_1_33_2","first-page":"2","volume":"7","year":"1987","unstructured":"Martin DL. Regulatory properties of brain glutamate decarboxylase. Cell Mol Neurobiol 1987;7:237\u2013253.","journal-title":"Cell Mol Neurobiol"},{"key":"e_1_3_1_34_2","first-page":"3","volume":"60","year":"1993","unstructured":"Martin DL, Rimvall K. Regulation of gamma-aminobutyric acid synthesis in the brain. J Neurochem 1993;60:395\u2013407.","journal-title":"J Neurochem"},{"key":"e_1_3_1_35_2","first-page":"2","volume":"16","year":"1991","unstructured":"Erlander MG, Tobin AJ. The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem Res 1991;16:215\u2013226.","journal-title":"Neurochem Res"},{"key":"e_1_3_1_36_2","first-page":"9","volume":"7","year":"1991","unstructured":"Erlander MG, Tillakaratne NJK, Feldblum S, Patel N, Tobin AJ. Two genes encode distinct glutamate decarboxylases. Neuron 1991;7:91\u2013100.","journal-title":"Neuron"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.46.5.1459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:11:00Z","timestamp":1711548660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.46.5.1459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,5]]}},"alternative-id":["10.1212\/WNL.46.5.1459"],"URL":"https:\/\/doi.org\/10.1212\/wnl.46.5.1459","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,5]]}}}